<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1563">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140811</url>
  </required_header>
  <id_info>
    <org_study_id>IMM01-02</org_study_id>
    <nct_id>NCT05140811</nct_id>
  </id_info>
  <brief_title>A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome</brief_title>
  <official_title>Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an open-lable , multi-center, Phase 1/Phase 2 study that will evaluate the&#xD;
      safety, tolerability, Pharmacokinetics, Pharmacodynamics and and immunogenicity of IMM01&#xD;
      combined with Azacitidine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic&#xD;
      Syndrome (MDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main study purpose:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of IMM01 combined with Azacitidine in patients&#xD;
           with AML and MDS.&#xD;
&#xD;
        -  To explore the Maximum Tolerated Dose (MTD) of IMM01 combined with Azacitidine, and&#xD;
           determine the phase 2 clinical recommended dose (RP2D) of IMM01 combined with&#xD;
           Azacitidine.&#xD;
&#xD;
      Secondary study purpose:&#xD;
&#xD;
        -  To evaluate the efficacy of IMM01 combined with Azacitidine in patients with AML and&#xD;
           MDS.&#xD;
&#xD;
        -  To evaluate the Pharmacokinetics and Pharmacodynamics of IMM01 combined with&#xD;
           Azacitidine, in patients with AML and MDS.&#xD;
&#xD;
      Exploratory study purpose:&#xD;
&#xD;
      • To evaluate the immunogenicity of IMM01 combined with Azacitidine in patients with AML and&#xD;
      MDS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate and the grade (severity) of dose-limiting toxicities (DLTs) of IMM01 combination azacitidine</measure>
    <time_frame>Though end of DLT evaluation period,up to approximately 28 days.</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Dose-limiting toxicities will be evaluated during the first cycle (28 days) of treatment.</time_frame>
    <description>MTD is the highest dose in patients with DLT incidence &lt;1/3.For a dose group to be assessed as MTD, at least 6 DLT data must be available to evaluate the subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).</time_frame>
    <description>Maximum observed concentration in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).</time_frame>
    <description>Area under the serum concentration - time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax</measure>
    <time_frame>Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).</time_frame>
    <description>Time to peak (maximum) serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - T1/2</measure>
    <time_frame>Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).</time_frame>
    <description>Terminal half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>When the last subject enrolled completes approximately 12 months of treatment</time_frame>
    <description>Response determined per European LeukemiaNet response criteria:&#xD;
CR = bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt; 1.0 x 10e9/L; platelet count &gt; 100 x 10e9/L; and independence of red cell transfusions.&#xD;
CRi = all CR criteria except for residual neutropenia (&lt; 1.0 x 10e9/L) or thrombocytopenia (&lt; 100 x 10e9/L)].&#xD;
To evaluate clinical benefit defined as CR, CRi, morphologic leukemia-free state, and partial remission (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Remission (OR):</measure>
    <time_frame>When the last subject enrolled completes approximately 12 months of treatment</time_frame>
    <description>Response Criteria are according to the Modified IWG (International Working Group) Response Criteria in Myelodysplasia.CR: bone marrow evaluation shows less than or equal to (&lt;=) 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin &gt;= 11 gram per deciliter (g/dL), neutrophils &gt;= 1000/mL, platelets &gt;= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by &gt;=50%, still greater than 5% in bone marrow. Hematologic improvement are measured in participants with pretreatment abnormal values: hemoglobin level less than 110 g/L (11 g/dL) or red blood count (RBC)-transfusion dependence, platelet count &lt;100 x 10^9/L or platelet-transfusion dependence, absolute neutrophil count (ANC) less than 1.0 x 10^9/L.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Endpoint</measure>
    <time_frame>In cycle 1(each cycle is 28 days) and cycle 4, 6, 8, 10, and 12, at the end of treatment or early study withdrawal, and 30 days after the last dose.</time_frame>
    <description>Anti-drug Antibody (ADA)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Relapse/Refractory AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM01 and Azacitidine in Relapse/Refractory AML&#xD;
Interventions:&#xD;
Drug: IMM01 Drug: Azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapsed or Refractory MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM01 and Azacitidine in Relapse/Refractory MDS&#xD;
Interventions:&#xD;
Drug: IMM01 Drug: Azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment naive AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM01 and Azacitidine in treatment naive AML&#xD;
Interventions:&#xD;
Drug: IMM01 Drug: Azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment naive MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM01 and Azacitidine in treatment naive MDS&#xD;
Interventions:&#xD;
Drug: IMM01 Drug: Azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMM01</intervention_name>
    <description>IMM01 is intravenously once a week, every 28 days for a treatment cycle;</description>
    <arm_group_label>Relapse/Refractory AML</arm_group_label>
    <arm_group_label>Relapsed or Refractory MDS</arm_group_label>
    <arm_group_label>Treatment naive AML</arm_group_label>
    <arm_group_label>Treatment naive MDS</arm_group_label>
    <other_name>IMM01 Ingection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles</description>
    <arm_group_label>Relapse/Refractory AML</arm_group_label>
    <arm_group_label>Relapsed or Refractory MDS</arm_group_label>
    <arm_group_label>Treatment naive AML</arm_group_label>
    <arm_group_label>Treatment naive MDS</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary participation and written informed consent.&#xD;
&#xD;
          2. Males and females ≥18 years of age&#xD;
&#xD;
          3. The Eastern Oncology Collaboration (ECOG) Status of ≤2&#xD;
&#xD;
          4. Life expectancy of at least 3 months.&#xD;
&#xD;
          5. Women and men of reproductive age must agree and use effective contraception during&#xD;
             the study period and for three months after the last administration of IMM01, and&#xD;
             women of reproductive age must have negative pregnancy test results within seven days&#xD;
             prior to administration.&#xD;
&#xD;
          6. White blood cell count ≤ 20×10⁹/L before the first treatment of the study drug&#xD;
             (treatment with hydroxyurea is permitted, but not within 3 days before the first&#xD;
             treatment of the study drug).&#xD;
&#xD;
          7. Bone marrow aspiration and bone marrow biopsy were agreed during screening and&#xD;
             treatment.&#xD;
&#xD;
          8. For those who have received previous chemotherapy or targeted drug therapy, the&#xD;
             interval between the first drug administration should be more than 2 weeks;Prior&#xD;
             treatment with chimeric antigen receptor T cells (CAR T cells) should be discontinued&#xD;
             for at least 12 weeks after initial dosing.&#xD;
&#xD;
          9. For those who had previously received chemotherapy and targeted drugs&#xD;
&#xD;
         10. Appropriate organ functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received anti-CD47 antibody or SIRPα fusion protein research drugs.&#xD;
&#xD;
          2. He has received allogeneic hematopoietic stem cell transplantation and other organ&#xD;
             transplants; Autologous hematopoietic stem cell transplantation less than six months.&#xD;
&#xD;
          3. Central nervous system leukemia orcentral nervous system invasion.&#xD;
&#xD;
          4. Developed other malignant tumors within 5 years prior to enrollment.Except:&#xD;
&#xD;
             Cured carcinoma in situ and non-melanoma skin cancer of the cervix; Complete remission&#xD;
             of disease at least 2 years prior to initial administration and no need for&#xD;
             antineoplastic therapy.&#xD;
&#xD;
          5. Patients with a history of active autoimmune diseases;&#xD;
&#xD;
          6. Major surgery within 4 weeks prior to initial treatment;&#xD;
&#xD;
          7. Subjects requiring systemic corticosteroids (equivalent to &gt;10 mg prednisone/day) or&#xD;
             other immunosuppressive agents within 14 days prior to initial treatment or during the&#xD;
             study period;&#xD;
&#xD;
          8. Hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥&#xD;
             90mmHg) or pulmonary hypertension or unstable angina that is also not controlled by&#xD;
             medication;&#xD;
&#xD;
          9. Patients with a history of arterial or deep vein thrombosis within the 6 months prior&#xD;
             to enrollment, or evidence or history of bleeding tendency within the 2 months prior&#xD;
             to enrollment, regardless of severity.&#xD;
&#xD;
         10. Severe gastrointestinal diseases;&#xD;
&#xD;
         11. With acute lung disease, pulmonary fibrosis, Severe dyspnea, lung insufficiency or&#xD;
             continuous oxygen inhalation.&#xD;
&#xD;
         12. Patients who have been severely infected within 4 weeks prior to initial&#xD;
             administration;&#xD;
&#xD;
         13. Active hepatitis B or hepatitis C ; human immunodeficiency virus (HIV) antibody is&#xD;
             positive.&#xD;
&#xD;
         14. Live attenuated vaccine should be administered within 4 weeks prior to initial&#xD;
             administration.&#xD;
&#xD;
         15. Patients with a history of severe allergy to protein drugs (CTCAE V5.0 grade &gt; 3); Or&#xD;
             the patient is allergic to azacytidine.&#xD;
&#xD;
         16. Participate in clinical trials of other drugs 28 days prior to initial dosing.&#xD;
&#xD;
         17. A history of prior neurological or mental disorders, such as epilepsy, dementia, or&#xD;
             alcohol, drug or substance abuse, affects compliance.&#xD;
&#xD;
         18. Other conditions that the investigator considers inappropriate for participation in&#xD;
             this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Huang, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP，Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Zhou, Medical Mornitor</last_name>
    <phone>13621857739</phone>
    <email>ping.zhou@immuneonco.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

